Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.
Fiche du document
2015
- doi: 10.1586/14737175.2015.1079130
- issn: 1473-7175
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1586/14737175.2015.1079130
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/26312647
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1473-7175; 1744-8360
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_66CFA03039466
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
TherapyCiter ce document
A. Vezzani et al., « Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. », Serveur académique Lausannois, ID : 10.1586/14737175.2015.1079130
Métriques
Partage / Export
Résumé
Status epilepticus (SE) is a life-threatening neurological emergency often refractory to available treatment options. It is a very heterogeneous condition in terms of clinical presentation and causes, which besides genetic, vascular and other structural causes also include CNS or severe systemic infections, sudden withdrawal from benzodiazepines or anticonvulsants and rare autoimmune etiologies. Treatment of SE is essentially based on expert opinions and antiepileptic drug treatment per se seems to have no major impact on prognosis. There is, therefore, urgent need of novel therapies that rely upon a better understanding of the basic mechanisms underlying this clinical condition. Accumulating evidence in animal models highlights that inflammation ensuing in the brain during SE may play a determinant role in ongoing seizures and their long-term detrimental consequences, independent of an infection or auto-immune cause; this evidence encourages reconsideration of the treatment flow in SE patients.